British drug maker AstraZeneca Plc (AZN.L, AZN) announced Tuesday positive data from global KOMET Phase III trial, in which Koselugo ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

High-level results of KOMET, the largest, global randomised double-blind placebo-controlled multicentre Phase III trial in adults with ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...

Also Read: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs ... Chronic rhinosinusitis with nasal polyps is a condition that can cause symptoms from sinus pain and nose stuffiness to loss of smell.

AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

7 Stroke Warning Signs 1 Month Before It Happens 2024 | Stroke Signs and Symptoms Video AstraZeneca backs US and China - but ...

Shares of AstraZeneca dropped more than 7% yesterday after the Chinese publication Yicai Global reported that dozens of ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

KarenAlert #KarenGoneWild #KarenEncounter #PublicFreakout #EntitledKaren #KarenMoment #KarenDrama #KarenChronicles ...

Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...

The treatment for ATTR in certain adults with polyneuropathy had just been recommended for approval across the European Union and had gained regulatory approval in the United States at the end of 2023 ...